Comparative Pharmacology
Head-to-head clinical analysis: CHOLESTYRAMINE LIGHT versus FLAVORED COLESTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLESTYRAMINE LIGHT versus FLAVORED COLESTID.
CHOLESTYRAMINE LIGHT vs FLAVORED COLESTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.
None Documented
None Documented
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Not applicable due to non-absorbable resin; systemic absorption is negligible. Terminal half-life not defined.
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Primarily fecal as insoluble complex (90-95%); <5% renal as glucuronide conjugate; minimal biliary elimination.
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant